Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

this amount, approximately 60% is attributed to pirfenidone which includes expenses for CAPACITY, RECAP, the preparation and support of NDA and MAA submissions and manufacturing.

Approximately 35% of the R&D expense is attributed to the company's one-third share of all development expenses incurred by the collaboration with Roche on ITMN-191. InterMune also is working to name a second-generation protease inhibitor under the Roche/InterMune collaboration. Roche is responsible for 100% of all R&D costs related to a second-generation protease inhibitor compound through Phase 1. After Phase 1, Roche pays two-thirds of all development costs related to the compound. The balance of 2009 R&D expense is related to the advancement of a named pirfenidone analog compound, ITMN-520, toward an expected IND filing in mid-2010.

G&A expense is anticipated to be in a range of approximately $35 to $40 million. The G&A guidance range includes approximately $5.0 million of various pirfenidone pre-marketing costs and a similar amount in legal fees associated with a Department of Justice (DOJ) action against a former InterMune executive covered by an indemnification agreement.

Other Expenses

InterMune will incur approximately $1 million in expenses recorded as Restructuring Charges related to a reduction in force in February 2009.

InterMune will pay a milestone of $13.5 million, which will be expensed as Acquired R&D and Milestone Expense in 2009, to Marnac and KDL in accordance with the pirfenidone purchase agreement and the company's decision to submit NDA and MAA filings on pirfenidone.

Other Uses of Cash in 2009

The company provided information to further guide investors on uses of cash in 2009.

According to the structure of the company's collaboration agreement with Roche, approximately $11.4 million of 2008 expenses on IT
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:9/30/2014)... release is available in German . ... around several quantum dots in a semiconductor layer. Quantum dots ... of atomic processes. If a short laser pulse is fired ... the quantum dot experiences a change in the electromagnetic field ... the emission of light by the dot. As soon as ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... significance of this past Sunday? , ,Yes, it was Mother's ... Day ("Victory in Europe"), but it was also the 106th ... of the world's greatest economists. These days, while Hayek is ... seminal work "The Road to Serfdom," he was also a ...
...
... a $75,000 grant to make the financial relationships and ... , ,The grant came from the Joyce Foundation , ... , ,All the information is already available, but not always ... with keeping track of the financial relationships of state officials, ...
Cached Biology Technology:Midwest cities in fight over municipal broadband access 2Midwest cities in fight over municipal broadband access 3Midwest cities in fight over municipal broadband access 4Ethics Board to put financial disclosures online with new grant 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... announced today the launch of its newest journal, ... in January 2012. Cell Reports , the first open-access ... the entire life science spectrum. The journal will focus on ... articles. As with all Cell Press journals, the primary criterion ...
... 1, 2011 /PRNewswire-Asia/ -- Clearbridge Accelerator announced today that ... well-established venture capitalist based in the Silicon Valley. Mr ... of Draper Fisher Jurvetson (DFJ), is well known for ... Clearbridge Accelerator is a technology incubator ...
... of the International Osteoporosis Foundation (IOF) has issued ... the efficacy and safety of two minimally invasive ... (VP) and balloon kyphoplasty (BKP). The review also ... future studies and highlights research questions still unresolved. ...
Cached Biology News:Announcing Cell Reports -- a new open-access journal from Cell Press 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6IOF urges systematic osteoporosis management after vertebral fracture augmentation 2
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
Biology Products: